

OFFICIAL  
FAX RECEIVED

JUN 27 2002

GROUP 1600

- 12. The method of claim 11, wherein the radiation is said UVA radiation.–
- 13. The method of claim 11, wherein the radiation is said UVB radiation.–
- 14. The method of claim 13, wherein the amount of radiation with which the patient is illuminated is erythemaL.–
- 15. The method of claim 13, wherein the amount of radiation with which the patient is exposed is suberythemaL.–
- 16. The method of claim 12, wherein the treatment is ongoing, and wherein, as the patient presents with a tanning response, the patient is illuminated with said UVB radiation.–
- 17. The method of claim 16, wherein the patient is exposed to both said UVA and said UVB radiation after said tanning response.–
- 18. The method of claim 16, wherein the radiation with which the patient is exposed is changed from said UVA radiation to said UVB radiation.–

#### REMARKS

Entry of the foregoing amendments are respectfully requested.


New claim 11 is effectively a linking claim and supported at least by the disclosure at page 12, lines 9-12, that the discovery that only certain UV wavelengths induce MMPs can be used to treat fibrotic conditions. Dependent claims 16-18 are supported at least by the disclosure at page 12, that UVB is better for darker skin, hence if the patient undergoing UVA treatment starts to

exhibit a tanning response, then UVB is added (claim 17) or the treatment is changed to use UVB only (claim 18). No new matter is added.

Fees

Please charge Deposit Account 502144 for the \$ 84.00 fee under 37 C.F.R. § 1.16(b) for the extra independent claim.

Respectfully submitted,

  
\_\_\_\_\_  
Bradley N. Ruben, Reg. No. 32,058

Bradley N. Ruben, PC  
463 First St., Suite 5A  
Hoboken, NJ 07030-1859

201-239-0707 (fax -0734)

mail@rubenpatent.com

26 June 2002

**CERTIFICATE OF MAILING OR  
TRANSMISSION – 37 CFR 1.8**

I hereby certify that I have a reasonable basis that this paper, along with any referred to above, (i) are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231, or (ii) are being transmitted to the U.S. Patent & Trademark Office in accordance with 37 CFR § 1.6(d).

DATE: 26 June 2002

NAME: Brad Ruben

SIGNATURE: Brad Ruben